OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MLCM.I58

Malin Corporation PLC

PharmaceuticalsVerified

Malin Corporation PLC has a fully diluted share count of 4,326,168, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's valuation snapshot is not available, limiting the ability to assess its relative value compared to industry peers. The company's profitability and return metrics are not available in the current dataset, making it difficult to compare its performance against the preferred metrics for the Pharmaceuticals industry, such as EBITDA margin or ROIC. Without these metrics, it is not possible to determine whether Malin Corporation PLC is outperforming or underperforming the industry median. Malin Corporation PLC's revenue concentration by segment and geography is not disclosed in the available data, which limits the ability to assess the company's exposure to specific markets or product lines. This lack of transparency could pose a risk to investors seeking to understand the company's diversification and resilience to regional or product-specific shocks. The company's growth trajectory is not quantified in the current dataset, as no outlook data is available for the current or next fiscal year. Analysts have provided a mean price target of 15.50 EUR, with a median and high target also at 15.50 EUR, and a mean recommendation of 2.00 (indicating a "Buy" rating). However, the absence of revenue history and growth projections makes it difficult to assess the company's long-term potential. The company's risk profile is characterized by low dilution risk and an inability to assess liquidity risk due to missing balance-sheet data. No recent events, such as filings or transcripts, are available to provide additional context on the company's strategic direction or operational performance. No recent events, such as earnings calls, regulatory filings, or press releases, are available in the current dataset to provide insight into the company's recent performance or strategic initiatives.

30-day price · MLCM.I-0.25 (-3.2%)
Low$7.45High$8.45Close$7.45As of17 May, 00:00 UTC
Profile
CompanyMalin Corporation PLC
TickerMLCM.I
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Malin Corporation PLC is a pharmaceutical company focused on the development and commercialization of medical devices and specialty pharmaceutical products, primarily in the areas of pain management and urology.

Classification. Malin Corporation PLC is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a classification confidence of 0.92.

Malin Corporation PLC has a fully diluted share count of 4,326,168, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's valuation snapshot is not available, limiting the ability to assess its relative value compared to industry peers. The company's profitability and return metrics are not available in the current dataset, making it difficult to compare its performance against the preferred metrics for the Pharmaceuticals industry, such as EBITDA margin or ROIC. Without these metrics, it is not possible to determine whether Malin Corporation PLC is outperforming or underperforming the industry median. Malin Corporation PLC's revenue concentration by segment and geography is not disclosed in the available data, which limits the ability to assess the company's exposure to specific markets or product lines. This lack of transparency could pose a risk to investors seeking to understand the company's diversification and resilience to regional or product-specific shocks. The company's growth trajectory is not quantified in the current dataset, as no outlook data is available for the current or next fiscal year. Analysts have provided a mean price target of 15.50 EUR, with a median and high target also at 15.50 EUR, and a mean recommendation of 2.00 (indicating a "Buy" rating). However, the absence of revenue history and growth projections makes it difficult to assess the company's long-term potential. The company's risk profile is characterized by low dilution risk and an inability to assess liquidity risk due to missing balance-sheet data. No recent events, such as filings or transcripts, are available to provide additional context on the company's strategic direction or operational performance. No recent events, such as earnings calls, regulatory filings, or press releases, are available in the current dataset to provide insight into the company's recent performance or strategic initiatives.
Key takeaways
  • Malin Corporation PLC has no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities.
  • Analysts have assigned a "Buy" rating to Malin Corporation PLC, with a mean price target of 15.50 EUR.
  • The company's profitability and return metrics are not available, making it difficult to assess its performance against industry peers.
  • Revenue concentration by segment and geography is not disclosed, limiting the ability to assess the company's diversification and resilience.
  • The company's growth trajectory is not quantified in the current dataset, and no outlook data is available for the current or next fiscal year.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4-$5.7M$87.7M$91.7M
FY-3-$5.1M$37.8M$2.0M
FY-2-$3.8M$12.9M$13.2M
FY-1-$4.5M$0.00$200.0k
FY0-$2.5M$0.00$100.0k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$370.6M$279.8M
FY-3$228.2M$218.9M$32.7M
FY-2$287.9M$283.1M$173.9M
FY-1$116.6M$109.5M$29.3M
FY0$198.5M$193.2M$62.1M
PeriodOCFCapExFCFSBC
FY-4-$3.0M-$2.1M$91.7M
FY-3-$4.6M-$1.6M$2.0M
FY-2-$7.2M$0.00$13.2M
FY-1-$3.2M$200.0k
FY0-$1.3M$100.0k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricMLCM.IActivity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Observations
IR observations
Mean price target15.50 EUR
Median price target15.50 EUR
High price target15.50 EUR
Low price target15.50 EUR
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 13:38 UTC#73f3b38e
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 14:25 UTCJob: e2a00194